605507.SS Stock Analysis
60
Uncovered
Guobang Pharma Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Guobang Pharma Ltd. engages in the research, development, manufacturing and sale of pharmaceutical products. The company is headquartered in Shaoxing, Zhejiang and currently employs 3,326 full-time employees. The company went IPO on 2021-08-02. The firm's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.